About the book
Despite remarkable advances in our understanding of the drivers of human malignancies, new targeted therapies often fail to perform sufficiently in clinical trials. Indeed, the cost of bringing a new agent to market has risen substantially in the last several decades, fuelled partly by lack of efficacy in late phase clinical trials.
New advances in computational modelling are beginning to show signs of reversing this trend. Artificial Intelligence (AI) allows complex and disparate datasets to be combined and analysed on an unprecedented scale, including in the modelling and simulation of drug targets and the clinical trials through which new drugs are tested, and approved for use, on patients.
As AI technologies become mainstream, we will begin a new chapter in our understanding of the complex causes and consequences of cancer development. It is hoped that this new era of research will lead to insights that can be translated into increased efficiencies in the drug discovery and development process.
In this book, we will look at the ways in which AI supports the design, development and analysis of oncology drugs, and look to a future of AI led therapeutic development and clinical trial design, with lower costs and increased success rates.